IN THE CLAIMS:

This listing of claims will replace all prior versions and listing of claims in the application.

Listing of claims:

Claim 1 (**currently amended**): A compound of formula (**I**):



(I)

wherein:

R^1 is halo, cyano, C_{1-3}alkyl or C_{1-3}alkoxy;

p is 0-2; wherein the values of R^1 may be the same or different;

R^2 is C_{1-4}alkyl, C_{2-4}alkenyl, C_{2-4}alkynyl, C_{3-6}cycloalkyl, C_{3-6}cycloalkylC_{1-3}alkyl, a heterocyclyl or heterocyclylC_{1-3}alkyl; wherein R^2 may be optionally substituted on carbon by one or more methyl, ethyl, methoxy, ethoxy, propoxy, trifluoromethyl, trifluoromethoxy, 2,2,2-trifluoroethoxy or cyclopropylmethoxy; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by one or more methyl, ethyl, acetyl, 2,2,2-trifluoroethyl or methoxyethyl;

R^3 is hydrogen, halo or cyano;

R^4 is C_{1-6}alkyl or C_{1-6}alkoxyC_{1-6}alkyl;

R^5 is substituted methyl, optionally substituted C_{2-6}alkyl or optionally substituted C_{2-6}alkenyl; wherein said substituents are selected from one or more methoxy, ethoxy, propoxy, trifluoromethyl, trifluoromethoxy, 2,2,2-trifluoroethoxy or cyclopropylmethoxy;

or a pharmaceutically acceptable salt ~~or an *in vivo* hydrolysable ester~~ thereof;

provided that the compound is not 4-(1-methyl-2-ethylimidazol-5-yl)-2-{4-[*N*-(tetrahydrofur-2-ylmethyl)sulphamoyl]anilino}pyrimidine; 4-(1-methyl-2-ethyl-imidazol-5-yl)-2-{4-[*N*-(2-

methoxyethyl)sulphamoyl]anilino}pyrimidine; 4-(1-methyl-2-isopropyl-imidazol-5-yl)-2-{4-[*N*-(2-methoxyethyl)sulphamoyl]anilino}pyrimidine; 4-(1-methyl-2-isopropyl-imidazol-5-yl)-2-{4-[*N*-(cyclopropylmethyl) sulphamoyl]anilino}pyrimidine; 4-(1-methyl-2-isopropyl-imidazol-5-yl)-2-{4-[*N*-(tetrahydrofur-2-ylmethyl)sulphamoyl]anilino}pyrimidine; 4-(1-methyl-2-ethylimidazol-5-yl)-2-{4-[*N*-(cyclopropylmethyl) sulphamoyl]anilino}pyrimidine; 4-(1-methyl-2-ethyl-imidazol-5-yl)-2-[4-(*N*-cyclopropylsulphamoyl) anilino]pyrimidine; 4-(1-methyl-2-ethylimidazol-5-yl)-2-[4-(*N*-cyclobutyl-sulphamoyl) anilino]pyrimidine; or 4-(1-methyl-2-methoxymethylimidazol-5-yl)-2-{4-[*N*-(2-methoxyethyl) sulphamoyl]anilino}pyrimidine.

Claim 2 (**currently amended**): Thecompound of formula **(I)** according to claim 1 wherein p is 0; or a pharmaceutically acceptable salt ~~or an *in vivo* hydrolysable ester~~ thereof.

Claim 3 (**currently amended**): The compound of formula **(I)** according to claim 1 wherein R^2 is C_{1-4}alkyl, C_{2-4}alkenyl, C_{3-6}cycloalkyl, C_{3-6}cycloalkylC_{1-3}alkyl or heterocyclylC_{1-3}alkyl; wherein R^2 may be optionally substituted on carbon by one or more methoxy, ethoxy or trifluoromethyl; or a pharmaceutically acceptable salt ~~or an *in vivo* hydrolysable ester~~ thereof.

Claim 4 (**currently amended**): The compound of formula **(I)** according to claim 1 wherein R^3 is hydrogen; or a pharmaceutically acceptable salt ~~or an *in vivo* hydrolysable ester~~ thereof.

Claim 5 (**currently amended**): The compound of formula **(I)** according to claim 1 wherein R^4 is C_{1-4}alkyl or C_{1-4}alkoxyC_{1-4}alkyl; or a pharmaceutically acceptable salt ~~or an *in vivo* hydrolysable ester~~ thereof.

Claim 6 (**currently amended**): The compound of formula **(I)** according to claim 1 wherein R^5 is substituted methyl or optionally substituted C_{2-6}alkyl; wherein said substituents are selected from one or more methoxy; or a pharmaceutically acceptable salt ~~or an *in vivo* hydrolysable ester~~ thereof.

Claim 7 (**currently amended**): The compound of formula **(I)** as claimed in claim 1 wherein:

p is 0;

R^2 is 2-ethoxyethyl, 2-methoxyethyl, 2,2,2-trifluoroethyl, 3-methoxypropyl, *t*-butyl, allyl, cyclopropyl, cyclobutyl, cyclopropylmethyl or tetrahydrofur-2-ylmethyl;

R^3 is hydrogen;

R^4 is methyl, ethyl, isopropyl or 1-methoxyprop-2-yl; or

R^5 is methoxymethyl, isopropyl, ethyl, butyl or 3,3-dimethylbutyl;

or a pharmaceutically acceptable salt ~~or an *in vivo* hydrolysable ester~~ thereof;

provided that the compound is not 4-(1-methyl-2-ethylimidazol-5-yl)-2-{4-[*N*-(tetrahydrofur-2-ylmethyl)sulphamoyl]anilino}pyrimidine; 4-(1-methyl-2-ethyl-imidazol-5-yl)-2-{4-[*N*-(2-methoxyethyl)sulphamoyl]anilino}pyrimidine; 4-(1-methyl-2-isopropyl-imidazol-5-yl)-2-{4-[*N*-(2-methoxyethyl)sulphamoyl]anilino}pyrimidine; 4-(1-methyl-2-isopropyl-imidazol-5-yl)-2-{4-[*N*-(cyclopropylmethyl) sulphamoyl]anilino}pyrimidine; 4-(1-methyl-2-isopropyl-imidazol-5-yl)-2-{4-[*N*-(tetrahydrofur-2-ylmethyl)sulphamoyl]anilino}pyrimidine; 4-(1-methyl-2-ethylimidazol-5-yl)-2-{4-[*N*-(cyclopropylmethyl) sulphamoyl]anilino}pyrimidine; 4-(1-methyl-2-ethyl-imidazol-5-yl)-2-[4-(*N*-cyclopropylsulphamoyl) anilino]pyrimidine; 4-(1-methyl-2-ethylimidazol-5-yl)-2-[4-(*N*-cyclobutyl-sulphamoyl) anilino]pyrimidine; or 4-(1-methyl-2-methoxymethylimidazol-5-yl)-2-{4-[*N*-(2-methoxyethyl) sulphamoyl]anilino}pyrimidine.

Claim 8 (**currently amended**): The compound of formula **(I)** as claimed in claim 1 selected from:

4-(1,2-diethylimidazol-5-yl)-2-{4-[*N*-(2-ethoxyethyl)sulphamoyl]anilino}pyrimidine;

4-(1,2-diethylimidazol-5-yl)-2-{4-[*N*-(cyclopropyl)sulphamoyl]anilino}pyrimidine; and

4-(1,2-diethylimidazol-5-yl)-2-{4-[*N*-(allyl)sulphamoyl]anilino}pyrimidine;

or a pharmaceutically acceptable salt ~~or an *in vivo* hydrolysable ester~~ thereof;

Claim 9 (**currently amended**): A process for preparing a compound of formula **(I)** or a pharmaceutically acceptable salt ~~or an *in vivo* hydrolysable ester~~ thereof as claimed in claim 1,

which process (wherein R^1, R^2, R^3, R^4, R^5 and p are, unless otherwise specified, as defined in claim 1) comprises of:

Process a) reaction of a pyrimidine of formula **(II)**:



(II)

wherein L is a displaceable group; with an aniline of formula **(III)**:



(III)

Process b) reacting a compound of formula **(IV)**:



(IV)

with a compound of formula **(V)**:



(V)

wherein T is O or S; R^x may be the same or different and is C_{1-6}alkyl;

Process c) reacting a pyrimidine of formula **(VI)**:



(VI)

wherein X is a displaceable group; with an amine of formula **(VII)**:

R^2-NH_2

(VII)

or

Process d) reacting a pyrimidine of formula **(VIII)**



(VIII)

with a compound of formula **(IX)**:



(IX)

where Y is a displaceable group;

and thereafter, optionally:

i) converting a compound of the formula **(I)** into another compound of the formula **(I)**;

ii) removing any protecting groups;

iii) forming a pharmaceutically acceptable salt ~~or *in vivo* hydrolysable ester~~.

Claim 10 (**currently amended**): A pharmaceutical composition which comprises a compound of the formula **(I)**, or a pharmaceutically acceptable salt ~~or *in vivo* hydrolysable ester~~ thereof, according to claim 1, in association with a pharmaceutically-acceptable diluent or carrier.

Claims 11-20 (**cancelled**).

Claim 21 (**new**): A method for ~~producing a cell cycle inhibitory (anti-cell proliferation) effect~~ treating rheumatoid arthritis in a warm-blooded animal in need thereof, which comprises administering to said animal an effective amount of a compound of formula **(I)** or a pharmaceutically acceptable salt ~~or *in vivo* hydrolysable ester~~ thereof as claimed in claim 1.

Claimd 22-24 (**cancelled**).